Evidence map›Paper›PMID 40292315›Full record

ArticleiScience2025

Targeting CCR5 with miltefosine as a therapeutic strategy for thrombocytopenia.

Qinyao Li, Ting Zhang, Zhichao Li, Xiao Qi, Xinyue Mei, Sheng Liu, Siyu He, Gan Qiao, Rong Li, Hongping Shen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Qinyao LiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Ting ZhangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Zhichao LiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Xiao QiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Xinyue MeiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Sheng LiuDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Siyu HeDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Gan QiaoDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Rong LiDrug Discovery Research Center, Southwest Medical University, Luzhou, Sichuan 646000, China.
Hongping ShenClinical Trial Center, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Jing ZengDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Feihong HuangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Shuang DaiSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China.
Sirui LiSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China.
Jiesi LuoSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China.
Jianming WuDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Long WangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombocytopenia remains a challenging clinical condition with limited treatment options. Here, we demonstrated that miltefosine stimulated megakaryocyte (MK) differentiation

Indexed as

ImmunologyMolecular biology

Identifiers

PMID40292315
PMCPMC12032913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.